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Summary
Background: The management of epilepsy incurs significant costs to the United
Kingdom (UK) National Health Service (NHS). Making a diagnosis of epilepsy can,
however, be difficult and misdiagnosis frequently occurs when patients are seen by
non-specialists. This study estimates the financial costs of epilepsy misdiagnosis in the
NHS in England and Wales.
Methods: Standard costing methods were applied to estimate the costs attributable
to epilepsy misdiagnosis. The primary data were published in UK studies on the
prevalence of epilepsy, epilepsy misdiagnosis and costs identified from Medline,
Cinahl and Embase (1996—May 2006).
Results: An estimated total of 92,000 people were misdiagnosed with epilepsy in
EnglandandWales in2002.Theaveragemedical costperpatientperyearofmisdiagnosis
was £316, with the chief economic burdens being inpatient admissions (45%), inap-
propriate prescribing of antiepileptic drugs (AEDs) (26%), outpatient attendances (16%)
and general practitioner (GP) care (8%). The estimated annual medical costs in England
and Wales were £29,000,000, while total costs could reach up to £138,000,000 a year.
Conclusions: Allowing for uncertainty, and considering the analysis exclusively from
the NHS/CBS (community based services) perspective the opportunity costs of mis-
diagnosis are substantial. There is a need for health care commissioners to ensure that
misdiagnosis is kept to a minimum by ensuring that individuals with a recent onset
suspected seizure are seen as soon as possible by a specialist medical practitioner with
training and expertise in epilepsy.
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a Includes medical costs and community-based social services
costs. Medical resources include: hospital inpatient visits, anti-
epileptic medication, outpatient attendances, GP visits, A&E
attendances. Community based social services resources include:
health visitor, social worker, psychology/psychiatry, remedial
school, residential care and day care.Introduction
The management of epilepsy incurs significant costs
to the United Kingdom (UK) National Health Service
(NHS). The medical cost to the NHS in 1992/1993 of
newly diagnosed epilepsy in the first year of diag-
nosis was calculated as £18 million and the total
annual cost of established epilepsy estimated at
£2 billion, over 69% of which was due to unemploy-
ment and excess mortality (indirect costs).1 The
costs of treating epilepsy are likely to significantly
increase given the new trends in prescribing pat-
terns towards newer and more expensive antiepi-
leptic drugs (AEDs).2—4
A correct diagnosis of epilepsy requires that the
clinician differentiate between seizures and other
causes of transient neurological disturbance and
collapse, such as syncope, and between acute symp-
tomatic and unprovoked epileptic seizures. In an
individual diagnosed with epilepsy, it is important
that the correct classification of seizure type and
epilepsy syndrome is made so that the individual
with epilepsy can receive appropriate investiga-
tions, appropriate treatment, and information
about the likely prognosis of the seizure type
and/or syndrome.5—7,29
Making a diagnosis of epilepsy can be difficult.
Misdiagnosis is a frequent occurrence, occurring in
around 25% of cases.8,9 The majority of these
occur when the diagnosis is made by a non-spe-
cialist.9 Individuals misdiagnosed with epilepsy
may experience social and financial deprivation
as a result of having the wrong diagnostic label
and from side-effects of antiepileptic medica-
tion.10,11 In addition, there may be a risk of unne-
cessary teratogenicity as a result of antiepileptic
drug (AED) therapy in women incorrectly diag-
nosed as having epilepsy. In a small number of
cases, individuals may die prematurely because
the correct diagnosis was not made.12 Individuals
who have symptoms due to epileptic seizures but
who are wrongly diagnosed as having psychiatric or
associated disorders are disadvantaged by being
labelled with an incorrect diagnosis and by the
effects of continuing seizure activity because AEDs
are not used.
In contrast to the documented physical and
psychosocial effects of epilepsy misdiagnosis, little
is known about the health economic costs of mis-
diagnosis in the United Kingdom (UK). The one
published cost of illness study of epilepsy in the
UK is now more than ten years old and focused on
epilepsy in general, not the specific costs of mis-
diagnosis.1 This study aimed to estimate the finan-
cial costs of epilepsy misdiagnosis in the NHS in
England and Wales.Methods
Standard costing methods13 were applied to esti-
mate the costs attributable to epilepsy misdiagno-
sis. The primary data were published UK studies on
the prevalence of epilepsy, epilepsy misdiagnosis
and costs identified from Medline, Cinahl and
Embase (1966—May 2006). A systematic literature
search was undertaken to identify these studies, the
details of which are reported elsewhere.7
Thetotal numberofmisdiagnosedcases inepilepsy
includes the number of true epilepsy cases diagnosed
as other non-epileptic conditions plus the number of
non-epileptic conditions diagnosed as epilepsy. The
analysis focused only on estimating the costs of other
conditionswronglydiagnosedasepilepsy(‘‘falseposi-
tives’’) because this is the most common form of
misdiagnosis and the majority of the published evi-
dence addresses this type of misdiagnosis.
The perspective of the reference case is that of
the National Health System (NHS) and Community
Based Services (CBS).a The complete financial bur-
den of epilepsy misdiagnosis can, however, only be
represented through a wider societal perspective,
that includes, for example, the lost productivity due
to morbidity or mortality for not treating the under-
lying condition and/or for being stigmatized as an
individual with epilepsy (such as problems with
employment or mobility problems due to driving
restrictions).
The following steps were taken: To estimate the number of misdiagnosed patients
in England and Wales assuming prevalence and
misdiagnosis rates based on published UK litera-
ture and applying these to the 2002 population of
England and Wales. Only UK prevalence and mis-
diagnosis studies were included as it is important
that these estimates can be generalised to the
England and Wales population. In particular, var-
iations in health care systems mean that misdiag-
nosis rates from non-UK settings are unlikely to be
generalisable. To estimate the annual average uses of resources
and costs incurred by a misdiagnosed individual
based on assumptions derived from published
literature. All costs are estimated at 2003/4
prices adjusted for inflation by the hospital and
community health and services (HCHS) pay and
price index.14
600
A
.
Ju
are
z-G
arcia
e
t
al.
Table 1 Summary of published UK studies on epilepsy misdiagnosis
Evidence/author-studies Scheepers et al. 8 Smith et al. 9 Zaidi et al. 11 Leach et al. 21 Beach and Reading 22
Misdiagnosis rate 23.2% (49/212) min,
(35%)max
26.1% (46/184) 41.9% (31/74) Overall 16.3% (45/275).
18.9% (42/222) initially
diagnosed by non-
specialists; 5.6% (3/53)
initially diagnosed by
neurologists
32% (29/90) of children
classified as possible
epilepsy did not have
epilepsy
Rate of misdiagnosis according to underlying condition
Syncope and cerebrovascular 20/214 (7.07% and
2.35% respectively,
total 9.3%)
13/184 (7.06%) 19/74 (25.7%)
Psychogenic/NEA 10/214, 4.6%
(psychopathology)
19/184 (10.32%) 2/74 (2.7%)
Mixed diagnosis 6/ 184 (3.26%)
One seizure 7/214 (3.3%)
Alcohol related 6/214 (2.83%)
Migraine 3/214(1.41%)
Other 3/214 (1.41%) 8/184 (4.34%)
Method of detecting
misdiagnosis
-Specialist (clinical)
where required:
-Specialist (clinical)
where required:
-Head up tilt test and
carotid sinus massage
during continuous
electrocardiography
Reassessment by experienced
specialists. Data collection
included history of seizure
disorder, results of previous
investigations and nature of
all current and previous
treatments
Reassessment. Cases
were classified by
diagnosis at entry
and 6—30 months later
-EEG -IEEG
-Electroencephalography
-MRI -AEEG
-Blood pressure monitoring
-head up tilting -Imaging
-ECG (on 10 patients)
Patient group
selection
Population
based study
Group of patients
referred with
‘refractory epilepsy’
to epileptic clinic
and taking epileptic
medication
Patients referred to a
specialist clinic with
recurrent seizure-like
episodes.
Population
based study
Children with new
presentations of
paroxysmal disorders
in a district hospital
Notes Defined as cases of
diagnostic doubt
after reassessment
The costs of epilepsy misdiagnosis in England and Wales 601 Tb Only two cost of illness studies were found for the UK.8,23
Based on date of publication Jacoby’s paper was used for the
reference case.
c With an average cost of community based services (excluding
GP services) of £1179 per patient (2003/2004 prices).
d A third paper by Zaidi A. et al. 11 that reported misdiagnosis
frequency by cause was identified. However, the focus of this
study is on the identification of cardiovascular syncope in patients
with apparent treatment-resistant epilepsy.o estimate national figures of the cost conse-
quences of epilepsy misdiagnosis by extrapolating
the average estimated annual cost per individual
to the estimated national number of misdiag-
nosed cases.
Results
Prevalence and misdiagnosis in the UK-
literature review
Although epilepsy is the most common and one of
the most serious neurological disorders worldwide,
few studies that have examined its prevalence in
the UK and these have examined relatively small
populations. Also, most of these studies have used
different methodologies and definitions and are
based in different settings. From these studies,
the prevalence of active epilepsy ranges between
4 and 10 cases per 1000.2,15—20 This analysis used
Purcell and colleague’s prevalence of 7.7 cases of
active epilepsy per 1000 to inform the reference
case as this was a large recent population-based
study conducted in England and Wales. To ensure
that the findings took account of variations in pre-
valence we used two other UK population based
studies to perform a sensitivity analysis on the main
results.
Five primary papers were identified that assessed
the frequency and causes of misdiagnosis in the
UK.8,9,11,21,22 (Table 1) There was heterogeneity
among the studies as regard to population group
selection andmethods of analysis, with misdiagnosis
rates ranging from 16% to 32% (Table 1). Scheepers’
study was used to inform the reference case on the
basis that it is the only population-based study that
also reported the rate of misdiagnosis according to
underlying condition. To ensure that the findings
took account of variations in misdiagnosis rates
we used the other published studies to perform a
sensitivity analysis on the main results.
Considering a population of 52,000,000 in Eng-
land and Wales (according to the 2002 census) and
assuming an epilepsy prevalence of 7.7/1000 and a
misdiagnosis rate of 23% an estimated total of
92,000 people were misdiagnosed with epilepsy in
England and Wales in 2002.
Annual average use of resources and costs
incurred by a misdiagnosed individual
based on assumptions derived from
published literature
When possible a cost for the use of resources by
misdiagnosed patients was used. However, only onepaper was found to describe the use of medical
resources by a group of misdiagnosed individuals
because of their ‘epilepsy’8 and no study was found
to describe the use of community social services
resources bymisdiagnosed patients. When data were
unavailable average cost estimates reported in the
literature for epilepsy patients were assumed.b
The average medical cost per patient per year of
misdiagnosis was £316, with the chief economic
burdens being inpatient admissions (45%), inap-
propriate prescribing of AEDs (26%), outpatient
attendances (16%) and GP care (8%) (Table 2). The
estimated annual medical costs in England and
Wales were £29,000,000 while total costs (including
CBS costsc) could reach up to £138,000,000 a year.
Sensitivity analysis
Changing the reference case and using the lowest
prevalence data published in the UK for the general
population of 4.3/100017 total cost estimates
decrease to £76, 000,000 a year (Table 2). Instead
if the highest prevalence data published for the UKof
9/100018 is used total costs could reach up to
£161,000,000. If sensitivity analysis is performed
on the reference case using a misdiagnosis rate of
16.321 the estimated total cost is £97,000,000. Com-
bining prevalence and misdiagnosis rates that gives
the lowest possible estimation for total costs (using
misdiagnosis rate of 4.3/1000 and misdiagnosis rate
of 16.3%) yields a total cost around £54, 000, 000.
The cost consequences of epilepsy
misdiagnosis by true underlying condition
Cardiovascular and psychological conditions consti-
tute the two groups systematically misdiagnosed as
epilepsy. The number of misdiagnosed persons by
real underlying condition was estimated. These
rates were used to estimate national figures of
misdiagnosed persons by the underlying condition
and then costs (estimated on previous section) were
assigned to these figures (Table 3). The two papers
identified that assessed frequency, causes and con-
sequences misdiagnosis were used to set lower and
higher bounds on these estimations.d
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Table 2 The costs of epilepsy misdiagnosis in England and Wales
Base case Sensitivity analysis
Percent of
patients
in the
misdiagnosed
group that
used specific
resources
Unit
cost (£)
Annual
average
cost per
misdiagnosed
patient (£)
Total estimated
England and
Wales
misdiagnosis
cost per year(£) a
Total estimated
England and
Wales
misdiagnosis
cost per year(£)
Total estimated
England and
Wales
misdiagnosis
cost per year(£)
Total estimated
England and
Wales misdiagnosis
cost per year(£)
Total estimated
England and
Wales
misdiagnosis
cost per year(£)
Type of resource Prevalence rate
adjustment.
(Prevalence
4.3/1000 and
misdiagnosis 23%)
Misdiagnosis rate
adjustment.
(Prevalence
7.7/1000
misdiagnosis
16.3%)
Lowest value.
(Prevalence
4.3/1000 and
misdiagnosis
rate 16.3%)
Prevalence
adjustment and
highest value.
(Prevalence
9/1000 and
misdiagnosis
rate 23%)
Medical costs
Hospital inpatient
visits
8% 1741 142 13,087,605 (45%) 7,308,663 9,275,129 5,179,617 15,297,201
Antiepileptic
medication
39% 214 83 7,649,797 (26%) 4,271,965 5,421,378 3,027,523 8,941,322
Outpatient
attendances
(secondary care)
35% 147 51 4,700,478 (16%) 2,624,942 3,331,208 1,860,285 5,494,065
General practitioners
(GPs)b
25 2,304,156 (8%) 1,286,736 1,632,945 911,904 2,693,169
Accident and
emergency
attendances
18% 83 15 1,382,493 772,042 979,767 547,143 1,615,901
Total medical costs 316 29,124,530 (100%) 16,264,348 20,640,428 11,526,473 34,041,658
Total community-
based social
services costs
1179 108,702,814 60,682,487 77,009,697 43,005,415 127,009,857
Total costs 137,828,360 76,946,835 97,650,124 54,531,887 161,051,515
Bold text highlights parameters of sensitivity analysis.
a Distribution of medical costs as a percentage in parenthesis.
b GP number of consultations were not reported so average costs8 per patient on GP services were used.23
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Table 3 Costs and consequences of epilepsy misdiagnosis by true underlying condition
Misdiagnosed condition Numbera Medical
costs (£)
Community
costs (£)
Total
costs (£)
Cardiovascular Upper rangeb 37,619 11,887,978 44,368,496 56,256,474
Lower rangec 26,047 8,231,133 30,720,360 38,951,493
Psychological Upper rangec 38,069 12,030,117 44,898,988 56,929,105
Lower rangeb 18,809 5,943,989 22,184,248 28,128,237
a General misdiagnosis rate assumed at 23%.
b Assuming rates by misdiagnosed condition reported as 41% of total misdiagnosis for cardiovascular and cerebrovascular
misdiagnosed condition and 20% for psychopathological conditions.8
c Assuming rates bymisdiagnosed condition reported as 28% of total misdiagnosis for cardiovascular misdiagnosed condition and 41%
for psychopathological conditions.9Misdiagnosis of cases with a cardiovascular cause
was estimated to lead tomedical costs lying between
£8,200,000 and £12,000,000 and community services
related costs of £30,700,000 and £44,300,000. Mis-
diagnosis of cases with a psychological cause was
estimated to lead to direct medical costs of
£5,900,000 to £12,000,000 and community costs of
£ 22,000,000 to £44,900,000. Total costs upper range
estimation for cases with a cardiovascular cause was
£56,200,000 and for cases with a psychological cause
£56,900,000.Discussion
This study has shown that the financial cost of
epilepsy misdiagnosis to the NHS and community
based services (CBS) in England and Wales is con-
siderable. The estimated annual medical costs were
£29,1000,000 while total costs could reach up to
£137,800,000 a year with an average medical cost
per patient per year of misdiagnosis was £316. The
use of a sensitivity analysis, using lowest and highest
reported prevalence and misdiagnosis rates, allows
one to be reasonably certain that the ‘‘true’’ cost of
misdiagnosis lies between £54,000,000 and
£161,000,000. Thus, even allowing for uncertainty,
epilepsymisdiagnosis leads to a high cost for the NHS
and CBS in terms of the annual average use of
wasted resources.
This study highlights the serious health conse-
quences for the patients who are misdiagnosed and
notes the high rates of potentially avoidable inpati-
ent admissions, outpatient attendances and GP con-
sultations and the inappropriate prescribing of AEDs.
It is important, however, to point out that the
findings in this study have to be interpreted care-
fully as they have been obtained using published
data on epilepsy prevalence and misdiagnosis rates.
It is possible to be confident that the prevalence of
epilepsy in England andWales lies between 4.3 and 9
per 1000, as used in this study, as this is consistentwith other published UK and international preva-
lence studies of active epilepsy (5—10 per 1000).24
However, the data on misdiagnosis rates in the UK is
limited8,9 and, owing to variations in health care
systems, it is not possible to use non-UK data as a
comparison. Furthermore, misdiagnosis rates are
mainly based on studies focused on adult misdiagno-
sis. This is likely to mean that the magnitude of the
problem could be higher for children given that the
range of paroxysmal disorders occurring in children,
which are often misdiagnosed as epileptic seizures,
is far greater than that encountered in adults.25
Other important costs and consequences of mis-
diagnosis which are not considered in this study due
to lack of reliable data are: the cost of side effects
caused by incorrect treatment and the forgone
benefits in terms of health and quality of life when
receiving the correct treatment. Also, if the per-
spective of the analysis was widen to include patient
and societal costs it should have to consider the
costs for the individuals and their families (for
example, transport costs to the health centre hos-
pital) and the costs of legal settlements for both
misdiagnosed people and the NHS. In addition, cost
estimates could further increase if one would also
account for productivity loss due to unemployment
and excess mortality. For example, in one study9 23
out of 46 misdiagnosed persons were unemployed
(or had lost or been refused a job), or were under
threat of losing their job.
In conclusion, considering the analysis exclu-
sively from the NHS/CBS perspective, we can say
that the opportunity costs of misdiagnosis are sub-
stantial. This is especially true if it is considered
that a large amount of resources currently ‘lost’
could be used to give the correct treatment to
people misdiagnosed and to improve the quality
of the treatment received by individuals with epi-
lepsy. There is a need for health care commissioners
to ensure that misdiagnosis is kept to a minimum by
ensuring that recent national evidence-based clin-
ical guidelines on the management of epilepsy are
604 A. Juarez-Garcia et al.followed.7,26,27,29 Specifically, all individuals with a
recent onset suspected seizure need to be seen as
soon as possible by a specialist medical practitioner
with training and expertise in epilepsy. If it is not
possible to make a definite diagnosis of epilepsy
after this assessment then further investigations
and/or referral to a tertiary centre should be con-
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Jacoby et al. (cost per patient
using AEDs is £168)23Specialist visits NHS reference costs 2004 for
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